The Chemilogics™ Platform
Drug discovery with more certainty, less time
Empress uses AI to decode chemical programs written into genetic code, increasing certainty and speed to small molecule drugs.
Turning small molecule drug discovery inside out.
DNA to chemistry to medicines.
Our Chemilogics platform combines the proven advantages of small molecule chemistry with the programmability of biologics to fundamentally change the value and probability of success for small molecule drug discovery and create meaningful new medicines for patients around the world.
medicines from within
The Chemilogics™ Platform
Starting with clinical data, we find DNA sequences that encode the synthesis of small molecules that co-evolved with important disease targets inside the human body.
Using the power of genomics, AI, and synthetic biology, we can rapidly find, make, and test small molecules with desirable drug-like properties.
Find
Gather metagenomic data from tens of thousands of individuals worldwide
AI/ML maps biosynthetic pathways and disease linkages
Make
Test
.png)
Co-evolution has tested countless compounds in our bodies, over eons, and the encoded instructions can be found in biosynthetic DNA. We source metagenomic data from patients and use AI to identify, decode, and map these chemistries to health and disease.
Because DNA holds the instructions for small molecule synthesis, we can leverage proprietary synthetic biology tools to program cells to generate novel small molecules of interest.
We prioritize compounds that are novel, potent & specific against disease-relevant targets, and fulfill additional important drug-like qualifications.
Discover the power within
Developing transformative therapies, quickly, for a wide range of diseases
Identifying molecules that are already active in people provides a privileged starting point for generating new medicines.
In less than a year, we identified more than a dozen small molecules with proven pharmaceutical properties such as potency, specificity, and dose-dependent therapeutic activity.
Our initial portfolio of drug leads span multiple structural classes and target multiple classes of proteins, including cytokines, enzymes, GPCRs, and ion channels.
Programs based on these molecules and others offer the potential of new therapies to treat immune and inflammatory, metabolic, and neurological diseases, as well as pain and cancer.
Our mission is to make great medicines, fast.
